The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Shares of Recursion Pharmaceuticals (RXRX) spiked on Wednesday after the AI-driven drug developer significantly exceeded Street forecasts with its Q4 2025 financials, thanks primarily to a milestone ...

Sydney Sweeney as Millie and Amanda Seyfried as Nina in The Housemaid. Staff Writer Warning: This post contains spoilers for The Housemaid. If you're in the mood for a twisty, high-camp thriller full ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

Wicked: For Good concludes the tale of doomed friendship between Elphaba (Cynthia Erivo) and Glinda (Ariana Grande), turning to a new page in the Grimmerie as the story ends. The film is an ...

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. LONDON — In the year-plus since ...

Recursion Pharmaceuticals doesn't have any products on the market. In fact, none of the company's candidates are currently in phase 3 studies. So, despite the biotech's claims that its AI-powered ...

Recursion Pharmaceuticals uses AI to improve the process of discovering and developing drugs, making it easier and more cost-effective. Most medicines that enter clinical trials never reach the market ...

“The Long Walk” adaptation made a few key changes to the Stephen King story that might catch some fans off guard. The biggest change of the film came in the final moments. The winner of “The Long Walk ...

Weapons is a layered story told through different character perspectives, with a compelling metaphor at the heart of the film. In the very first scene, Weapons jumps right into its terrible ...

RXRX stock looks like a deep-value growth bet at just $5 and change. Though the technology is exciting, I’m not rushing into shares just yet. The analyst who called NVIDIA in 2010 just named his top ...